FDA approved GAMMAGARD LIQUID ERC for use, while EMA had already approved it as DEQSIGA. The company also benefited from market trends.
2 reports, 1 independent
Updated Jul 15
Gone quiet
- Reports
- 2
- Developments
- 1
- Repetition
- 50%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
FDA approved GAMMAGARD LIQUID ERC for use, while EMA had already approved it as DEQSIGA. The company also benefited from market trends.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
Related events
- Omeros Corporation's drug received FDA approval and is currently undergoing review by the European Medicines Agency.
- PolyPid Ltd's product received FDA Priority Review and gained single authorization across EU states from the EMA.
- Arise is seeking FDA approval for a drug as of October 7, 2026.
- Unregulated products are bypassing official government approval processes.
- Both the FDA and the European Medicines Agency govern drug approval processes.
Coverage
Newest first; wire copies grouped- Insider MonkeyTakeda Pharmaceutical (TAK) Gets GAMMAGARD LIQUID ERC Approved by FDA Takeda Pharmaceutical Company Limited (NYSE:TAK) is one of the 13 Best Japanese Stocks to Buy According to Hedge Funds. On June 3
- Unknown outlet